 |
Overview
Diabetes Drug-Induced Pancreatic and Thyroid Cancers
Drugs to treat diabetes have been available for many years. Their development by medical science has ushered in a new class of diabetes drugs referred to as “GLP-1 Agents” – so named for the human hormone which is the target of their action.
The GLP-1 agents come in two forms – injectibles and oral agents. The injectibles are Byetta (exenalide) and Victoza (liraglutide). The oral agents are Januvia (sitagliptin), Onglyza (saxagliptin) and Tradjenta (linagliptin).
Recent epidemiological studies have demonstrated an association between two of these agents – Byetta and Januvia – and pancreatic cancer. The studies also signaled an association between Byetta and Victoza and thyroid cancer.
If you or a loved one developed pancreatic or thyroid cancer while being treated with Byetta, Januvia and/or Victoza, we would like to speak with you. Please send us your contact information and we will contact you within 24 hours The GLP-1 Diabetes Medications – Mechanism of Action, Research Studies and FDA Statements
Meneo Law Group's team of dedicated professionals strives for excellence in all that we do. Our mission is to provide our clients with effective, professional and thorough legal representation and to do so in a diligent and ethical manner that helps our clients achieve and maximize their legal objectives.
DISCLAIMER
|
|
 |
|
GLP-1 Agents
In the News:
New York Times
Link: A Lone Voice Raises Alarms on Lucrative Diabetes Drugs
Investigation of Legal Implications
Our firm is currently investigating potential cases of GLP-1 drug-induced pancreatic and thyroid cancer on behalf of our clients. If you were (or a loved one was) taking Byetta, Januvia or Victoza and diagnosed with pancreatic or thyroid cancer, we would like the opportunity to talk with you.
No-Cost Review:
If you or a loved one developed pancreatic or thyroid cancer while being treated with Byetta, Januvia and/or Victoza, we would like to speak with you. Please send us your contact information and we will contact you within 24 hours
Patients should continue taking their medications as directed until they talk to their health care professionals
|
|
|
 |
 
|
If you or a loved one developed pancreatic or thyroid cancer while being treated with Byetta, Januvia and/or Victoza, we would like to speak with you. Please send us your contact information and we will contact you within 24 hours
|
|
|
A value is required.Invalid format.
|
